Back to Search
DAVID DRUCKER, M.D.
M.D.
Retina Specialist (Ophthalmology) Physician
NPI: 1386669562IndividualAccepts Medicare
Specialties, Licenses & Credentials
Retina Specialist (Ophthalmology) PhysicianPrimary
Ophthalmology — Retina Specialist
Code: 207WX0107X
MD00025765(WA)
CMS Specialties
PrimaryOPHTHALMOLOGY
Education
UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY
Class of 1984
Research & Publications (20)
Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes.
PMID 19116373·Am J Physiol Endocrinol Metab·2009
6-review
Normalization of obesity-associated insulin resistance through immunotherapy.
PMID 19633657·Nat Med·2009
7-preclinical
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents.
PMID 19597507·Nat Chem Biol·2009
7-preclinical
GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.
PMID 19151200·Diabetes·2009
7-preclinical
Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice.
PMID 18801896·Endocrinology·2009
7-preclinical
Different spatial scales of shape similarity representation in lateral and ventral LOC.
PMID 19176637·Cereb Cortex·2009
8-other
ErbB signaling is required for the proliferative actions of GLP-2 in the murine gut.
PMID 19523469·Gastroenterology·2009
7-preclinical
Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36.
PMID 19482026·Gastroenterology·2009
7-preclinical
The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action.
PMID 19008308·Endocrinology·2009
7-preclinical
Glucagon-like peptide-2 reduces intestinal permeability but does not modify the onset of type 1 diabetes in the nonobese diabetic mouse.
PMID 18845625·Endocrinology·2009
7-preclinical
Distinguishing conjoint and independent neural tuning for stimulus features with fMRI adaptation.
PMID 19357342·J Neurophysiol·2009
8-other
Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice.
PMID 19509017·Diabetes·2009
7-preclinical
Glucagon-like peptide-2 does not modify the growth or survival of murine or human intestinal tumor cells.
PMID 18829546·Cancer Res·2008
7-preclinical
The glucagon receptor is required for the adaptive metabolic response to fasting.
PMID 19046568·Cell Metab·2008
7-preclinical
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.
PMID 18782641·Lancet·2008
2-rct
Tissue-specific role of glycogen synthase kinase 3beta in glucose homeostasis and insulin action.
PMID 18694957·Mol Cell Biol·2008
7-preclinical
The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice.
PMID 18669601·Endocrinology·2008
7-preclinical
Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity.
PMID 18633100·Diabetes·2008
7-preclinical
Glucagon receptor signaling is essential for control of murine hepatocyte survival.
PMID 18809404·Gastroenterology·2008
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 3 locations total
- Address
- 1370 116th Ave NE Ste 110
Bellevue, WA 98004 - Phone
- (425) 454-2101
Quick Facts
- NPI
- 1386669562
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 3
- Years in Practice
- 42
- Publications
- 20
Are you this provider?
Claim Your Profile